Pfizer shares rose early Tuesday due to higher than expected demand for its COVID vaccine, but quickly sunk 2.3% after ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “2024 was a strong year of execution and performance for Pfizer in which we met or exceeded our strategic and ...

Pharmaceuticals giant Pfizer (NYSE:PFE) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. The company reported an adjusted earnings ...